Skip to content
Screener

Tango Therapeutics TNGX Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Amgen logo
AmgenAMGN
$937M-15.5%
Gilead Sciences logo
Gilead SciencesGILD
$535M
Exelixis logo
ExelixisEXEL
$650.47M+0.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$93.08M+21.7%
Erasca, Inc. logo
Erasca, Inc.ERAS
$67.71M-5.6%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemMarch 31, 2026December 31, 2025
Operating lease liabilities2,8322,738
Total current liabilities14,33021,679
Operating lease liabilities, net of current portion29,95630,832
Total liabilities44,28652,511
Commitments and contingencies (Note 7)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Stockholders' equity:
Common stock, $0.001 par value; 400,000,000 and 200,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 144,162,543 and 135,940,454 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively144136

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's total liabilities?
Tango Therapeutics (TNGX) reported total liabilities of $44.29M in Q1 2026.
How has Tango Therapeutics's total liabilities changed year-over-year?
Tango Therapeutics's total liabilities decreased by 58.8% year-over-year, from $107.55M to $44.29M.
What is the long-term trend for Tango Therapeutics's total liabilities?
Over 5 years (2020 to 2025), Tango Therapeutics's total liabilities has grown at a -20.8% compound annual growth rate (CAGR), from $168.65M to $52.51M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Tango Therapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude